Difference between revisions of "Bone sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf" to "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418") |
||
Line 25: | Line 25: | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
− | *[https://www.nccn.org/ | + | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418 NCCN Guidelines - Bone Cancer] |
*'''2013:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2013.0088 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/23744868/ PubMed] | *'''2013:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2013.0088 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/23744868/ PubMed] | ||
*'''2010:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2010.0051 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/20581300/ PubMed] | *'''2010:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2010.0051 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/20581300/ PubMed] |
Revision as of 18:00, 6 May 2024
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
0 regimens on this page
0 variants on this page
|
Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO/EURACAN/GENTURIS/PaedCan
- 2021: Strauss et al. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up PubMed
- 2018: Casali et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2014: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2012: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2010: Hogendoorn et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
- NCCN Guidelines - Bone Cancer
- 2013: Biermann et al. Bone cancer. PubMed
- 2010: Biermann et al. Bone cancer. PubMed
- 2007: Biermann et al. Bone cancer. PubMed
- 2005: Biermann et al. Bone cancer clinical practice guidelines. PubMed
Chondrosarcoma, all lines of therapy
- No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
- Mesenchymal chondrosarcoma has been treated with Ewing's sarcoma regimens
- Dedifferentiated chondrosarcoma has been treated with osteosarcoma regimens
Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy
- Undifferentiated pleomorphic sarcoma (UPS) of bone has been treated with osteosarcoma regimens